David Tang, OD
Optometrist · Virginia Beach, VANPI 1922006998
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,300 of the $28,503 with a category attached, or 71.2%. 23 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 57.7% of the total. Reporting peaked in 2021 at $15,847 and has fallen 87.0% since, to $2,054 in 2025. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $91.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$16K
- Alcon$9K
- Coopervision Inc.$711
- Tarsus Pharmaceuticals, Inc.$382
- AbbVie$374
- Dompe US, Inc.$337
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$20,30071%
- Food & beverage$8,20329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 58 | $16,433 |
| Alcon | 126 | $8,734 |
| Coopervision Inc. | 32 | $711 |
| Tarsus Pharmaceuticals, Inc. | 13 | $382 |
| AbbVie(2 entities) | 20 | $374 |
| Dompe US, Inc. | 11 | $337 |
| Sun Pharmaceutical Industries Inc. | 13 | $319 |
| Glaukos Corporation | 3 | $209 |
| Biotissue Holdings Inc. | 2 | $191 |
| Kala Pharmaceuticals, Inc. | 3 | $162 |
| Bausch & Lomb Americas Inc. | 8 | $144 |
| Oyster Point Pharma, Inc. | 3 | $81 |
| Harrow Eye, LLC | 3 | $64 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $58 |
| Ocular Therapeutix, Inc. | 2 | $56 |
| ABB Con-cise Optical Group LLC | 3 | $50 |
| Novartis | 2 | $46 |
| Thea Pharma Inc. | 2 | $42 |
| Amgen(2 entities) | 2 | $40 |
| Biogen | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Quidel Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$15,457
- DAILIES TOTAL1$5,256
- Precision 1$5,247
- Air Optix Color$5,000
- Rhopressa$246
- Rocklatan$246
- Precision7$149
- XDEMVY$125
- Clareon$122
- Oxervate$122
- SIMBRINZA$121
- INVELTYS$120
- TOTAL30$106
- Prokera$104
- iDoseTR$102
How this compares
$28,503 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $66,362 |
| XiidraLifitegrast | 21 | $25,372 |
| Cyclosporine | 13 | $9,233 |
| Loteprednol Etabonate | 14 | $2,826 |
| Brimonidine Tartrate | 13 | $1,239 |
| Latanoprost | 81 | $753 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $324 |
| Ofloxacin | 12 | $167 |
| Timolol Maleate | 15 | $166 |
| ErythromycinErythromycin Base | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $374 | $66,36257 claims |
| Bausch & Lomb Americas Inc.Xiidra | $144 | $25,37221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Virginia Beach
- Kurt DevitoVirginia Beach$54K
- Rahim KanjiVirginia Beach$10K
- Nainesh PithwaVirginia Beach$8K
- Kim-Chi PhamVirginia Beach$7K
- Glenn CoffinVirginia Beach$7K
- Elizabeth BaylorVirginia Beach$6K
- Walter WhitleyNorfolk$546K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.